Multiplex Assays: Evolving Technologies and Future Directions Report Now Available on R
05/05/2010

This report examines the role of multiplex and multi-analyte biomarker assays in translational medicine and their direct contributions to drug discovery and development; their contributions as theranostics, companion diagnostics, etc.; and the reasons why they are not more prevalent despite their apparent high potential

Online PR News – 05-May-2010 – – Dallas, TX: ReportsandReports announce it will carry Multiplex Assays: Evolving Technologies, Applications and Future Directions Market Research Report in its Store.

Multiplex Assays: Evolving Technologies, Applications and Future Directions focuses on significant recent developments in the multiplex assay field. Pharmaceutical companies are increasingly committing to associating their drugs with diagnostic assays. The majority of these are single-analyte biomarkers. However, a number of multiplex biomarkers not directly associated with particular drugs are in use as approved or homebrew diagnostics, and these contribute in various ways to the broad field of translational medicine. This report examines the role of multiplex and multi-analyte biomarker assays in translational medicine and their direct contributions to drug discovery and development; their contributions as theranostics, companion diagnostics, etc.; and the reasons why they are not more prevalent despite their apparent high potential. Key challenges and implications presented include: multi-analyte assays versus multiplex assays; the replacement of DNA microarrays with next-generation sequencing; recent developments and newer players in the field; the road toward validation and regulation; and the implications of recent deal activity. Multiplex Assays: Evolving Technologies, Applications and Future Directions examines applications of multiplex assays in translational medicine from the perspective of pharma R&D, companion diagnostic products, and the new diagnostics as a contributor to translational medicine.

Table Of Content

CHAPTER 1: INTRODUCTION

CHAPTER 2 : EVOLUTION OF MULTIPLEX ASSAYS AND TRANSLATIONAL MEDICINE

2.1: The Evolution of Now-Classical Diagnostic Biomarkers
Sensitivity, Specificity, and Predictive Value of Biomarker Assays
2.2: Pre-Genomic Biomarkers and Technologies
Enzyme and Metabolite Assays
Immunodiagnostics
Enzyme Immunoassays
Molecular Diagnostics
Target Amplification: Polymerase Chain Reaction
Signal Amplification Methods
2.3: Biomarkers in Drug Discovery and Development
2.4: Translational Medicine

CHAPTER 3: MULTIPLEX TECHNOLOGIES

3.1: Nucleic Acid-based Multiplex Assays
Two-Dimensional Positional Microarrays
Affymetrix
Agilent Technologies
Roche NimbleGen
Encoded Particle Arrays
Illumina
True Materials
NanoString
Next-Generation Sequencing as Competition for DNA Microarrays
Applied Biosystems
Roche’s NimbleGen
Agilent Technologies
Others
3.2: Multiplex Assays for Proteins
Mass Spectrometry
Positional Microarrays for Multiplex Protein Analysis
Randox Laboratories
Aushon Biosystems
Theranostics Health
Encoded Bead Technology
Luminex’s xMAP Bead Array
Bio-Rad
Biosite’s Triage Assays
Other
Theranos
3.3: Multiplex Assays for Small Molecule Metabolites
Metabolon
BG Medicine
Biosite

CHAPTER 4: APPLICATIONS

4.1: Pharma
Eli Lilly
Novartis
The Theranos Approach
4.2: Predictive Toxicology and Multiplex Biomarkers
4.3: Diagnostics
Ridge Diagnostics
Satoris
Rules-Based Medicine
Proteome Sciences
Tethys Bioscience
Pathwork Diagnostics
BioTheranostics
Health Discovery Corporation
Quest Diagnostics
Celera Corporation
Decision Biomarkers
Banyan Biomarkers

CHAPTER 5: MARKET-RELATED CONSIDERATIONS

5.1: The Competitive Environment
5.2 Deal Patterns
5.3 User Survey Results

CHAPTER 6: GENERAL OBSERVATIONS AND CONCLUSIONS

6.1 Issues Slowing the Deployment of Multiplex Biomarkers
6.2 Pharma’s Shift in R&D Emphasis
6.3 Translation in Theory versus Practice
6.4 Translational Medicine-How Well is it Working?
6.5 Discussion of User Survey Results

CHAPTER 7: INTERVIEW TRANSCRIPTS

David Lester, VP, Human Health Solutions, Theranos
Brian Edmonds, Ph.D., Research Advisor, Global External R&D, Eli Lilly
Stephen Naylor, Ph.D., Founder and Chairman of PPM, Inc.
Stephen A. Williams, M.D., Chief Medical Officer, SomaLogic
Michael Spain, M.D., Chief Medical Officer, Rules-Based Medicine
Peter Tolias, Ph.D., Executive Director, Institute of Genomic Medicine, Research Director, The Autism Center, University of Medicine & Dentistry of New Jersey

Browse the complete Report on: http://www.reportsandreports.com/market-reports/multiplex-assays-evolving-technologies-applications-and-future-/

Related Reports:
http://www.reportsandreports.com/market-reports/pharmacodynamic-assays/
http://www.reportsandreports.com/market-reports/h1n1-swine-influenza-market-assessment-latest-data-company-profi/
http://www.reportsandreports.com/market-reports/biomarkers-in-drug-discovery-optimizing-drug-discovery-timeline/

About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/